August 4, 2026 — Leads & Copy — Dyadic International, Inc., operating as Dyadic Applied BioSolutions, has announced an expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with an unidentified European biotechnology company. This collaboration focuses on additional precision-fermented dairy proteins, further bolstering Dyadic’s presence in the food and nutrition markets and aligning with its strategy to generate recurring revenue through partnerships and licensing.
The new program leverages Dyadic’s Dapibus™ precision fermentation platform, designed for the rapid development and cost-effective manufacturing of recombinant food proteins and enzymes. This platform utilizes established microbial fermentation processes and existing industrial infrastructure. The agreement expands Dyadic’s existing portfolio, which includes the commercial launch of recombinant bovine chymosin via Inzymes ApS and the ongoing development of recombinant bovine alpha-lactalbumin with BRIG BIO. These initiatives collectively demonstrate the Dapibus™ platform’s capability to produce commercially relevant dairy proteins and enzymes for various food and nutrition applications.
Dyadic’s commercialization strategy involves integrating strategic development partnerships with commercial participation. Under the terms of the agreement, Dyadic is set to receive development and commercial payments, licensing revenues, and potential economic participation tied to successful commercialization, creating multiple avenues for future revenue. The increasing demand for animal-free dairy ingredients, driven by food manufacturers seeking sustainable and high-quality alternatives that match the taste and performance of traditional dairy, underpins the market relevance of these developments. The proteins developed through this agreement are intended for a wide array of food and nutrition applications, aiming to enhance functionality, texture, and nutritional value in next-generation food ingredients.
The agreement highlights the versatility of the Dapibus™ platform in efficiently developing commercially viable dairy proteins and supporting clients from strain development to commercial manufacturing. Joe Hazelton, President and Chief Operating Officer of Dyadic Applied BioSolutions, stated that the agreement is a significant step in expanding the company’s food and nutrition pipeline. He emphasized that the Dapibus™ platform, combined with Dyadic’s commercialization model, offers opportunities for revenue generation through development fees, licensing, and future product sales. Hazelton added that each new program reinforces the Dapibus™ platform as a repeatable engine for commercial growth.
The program will now proceed with strain optimization, process development, and commercial scale-up activities. This announcement marks another milestone in Dyadic’s strategy to build a diversified portfolio of recombinant protein solutions across various markets, including bioindustrial and biopharmaceutical applications. The company believes its expanding commercial pipeline, strategic partnerships, and proprietary microbial expression platforms offer multiple pathways for future revenue through development agreements, commercial products, licensing, collaborations, and manufacturing opportunities.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that utilizes its proprietary microbial platforms to produce recombinant proteins. These proteins are sold or licensed to partners in the life sciences, food and nutrition, and bio-industrial markets. Dyadic’s C1 and Dapibus™ expression systems are designed to enable efficient, scalable, and sustainable product development for customers, forming the foundation of its growing portfolio of commercial and partnered programs.
Source: Dyadic International, Inc.
